TGF-βR2 and PD-1 (conditional bispecific)

Class

Conditionally-active bispecific antibody (TGF-β trap x PD-1)

Pathway

Blocks TGF-β-mediated immune evasion selectively in PD-1+ T cells; combined checkpoint/TGF-β blockade

This mechanism combines two immune-regulating strategies into a single conditionally-active antibody. PD-1 is an inhibitory receptor on T cells that, when engaged by its partner ligand, dampens the cell's ability to attack abnormal or infected tissue; blocking PD-1 is a well-established way to reawaken immune activity against tumors. TGF-β is a signaling protein that independently suppresses T cell function, promotes tissue remodeling, and is frequently elevated in tumors, where it helps cancer cells evade an activated immune response even after checkpoint blockade. Tumors often use TGF-β signaling as a parallel escape route when PD-1 alone is blocked, so pairing the two blockades can address resistance that either approach alone would miss. What distinguishes this molecule is that it is designed to neutralize TGF-β preferentially on T cells that already display PD-1, rather than throughout the body. Because TGF-β also performs necessary housekeeping roles in normal tissue, uncontrolled systemic blockade carries recognized biological trade-offs; restricting the effect to PD-1-marked, tumor-engaged T cells is a strategy intended to concentrate benefit while limiting exposure elsewhere. This dual, targeted approach is relevant broadly across immuno-oncology, particularly in cancers that respond poorly to checkpoint inhibition alone.